Janus Kinase Inhibitors

Janus Kinase Inhibitor

Arthritis, Rheumatoid

<section class="Section" data-sectioncode="34089-3"><a name="section-9"></a><h1>11 DESCRIPTION</h1>RINVOQ and RINVOQ LQ are formulated with upadacitinib, a JAK inhibitor. Upadacitinib has the following chemical name: (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1). The strength of upadacitinib is based on anhydrous upadacitinib. The solubility of upadacitinib in water is 38 to less than 0.2 mg/mL across a pH range of 2 to 9 at 37 oC. Upadacitinib has a molecular weight of 389.38 g/mol and a molecular formula of C17H19F3N6O • ½ H2O. The chemical structure of upadacitinib is: <img alt="upadacitinib-chem-structure" src="rinvoq-01.jpg"/>RINVOQ 15 mg extended-release tablets for oral administration are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, ferrosoferric oxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 30 mg extended-release tablets for oral administration are red, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a30’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 45 mg extended-release tablets for oral administration are yellow to mottled yellow, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a45’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide yellow, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide.RINVOQ LQ oral solution for oral administration is a 1 mg/mL clear, colorless to light yellow solution. Each 1 mL RINVOQ LQ contains 1 mg of upadacitinib as free base (equivalent to 1.02 mg upadacitinib hemihydrate) and the following inactive ingredients: citric acid anhydrous, purified water, sodium benzoate, sodium citrate dihydrate, and sucralose. </section>

Rinvoq

upadacitinib

24 HR upadacitinib 15 MG Extended Release Oral Tablet

24 HR upadacitinib 15 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 30 MG Extended Release Oral Tablet

24 HR upadacitinib 30 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 45 MG Extended Release Oral Tablet

24 HR upadacitinib 45 MG Extended Release Oral Tablet [Rinvoq]

upadacitinib 1 MG/ML Oral Solution

upadacitinib 1 MG/ML Oral Solution [Rinvoq]

Elixir Specialty Pharmacy

Actemra

Adbry

Afinitor

Alecensa

Alunbrug

Besponsa

Bosulif

Braftovi

Cabometyx

Cinqair

Cometriq

Cosentyx

Cotellic

Daurismo

Enbrel

Entyvio

Erivedge

Erleada

Farydak

Ibrance

Idhifa

Ilumya

Inlyta

Inqovi

Inrebic

Iressa

Jakafi

Lenvima

Lonsurf

Lorbrena

Lucentis

Lumakras

Lynparza

Mavenclad

Mayzent

Mekinist

Mektovi

Mylotarg

Nerlynx

Nexavar

Nubeqa

Ocrevus

Odomzo

Olumiant

Onureg

Piqray

Retevmo

Rituxan

Rozlytrek

Rubraca

Siliq

Stelara

Stivarga

Susvimo

Sutent

Synagis

Tabrecta

Tafinlar

Tagrisso

Talzenna

Targretin

Tasigna

Temodar

Tykerb

Tymlos

Vitravki

Vizimpro

Votrient

Xalkori

Xolair

Xtandi

Tonsa

Zelboraf

Zeposia

Zydelig

Zykadia

Rinvoq | Elixir Specialty Pharmacy

Which health plans does Elixir Specialty Pharmacy have contracts with?

Does Elixir Specialty Pharmacy work closely with Rinvoq and AbbVie Inc.?

Does Elixir Specialty Pharmacy offer services for Rinvoq patients?

What conditions does Elixir Specialty Pharmacy support?

How does Elixir Specialty Pharmacy help with insurance?